Olmesartan Medoxomil, Amlodipine And Hydrochlorothiazide Milpharm Limited (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan Medoxil, Amlodipine and Hydrochlorothiazide is indicated for the management of hypertension, acting on several complementary pathways to lower blood pressure.

• Hypertension: provides combined blockade of the renin‑angiotensin system, calcium‑channel mediated vasodilation and diuretic‑induced volume reduction.
• Chronic kidney disease with hypertension: helps achieve target blood pressure while offering renal‑protective effects.
• Heart failure with reduced ejection fraction (when added to standard therapy): contributes to after‑load reduction and symptom control.

• The combination product contains three agents that act synergistically: olmesartan medoxil blocks the AT1 receptor, preventing angiotensin II‑mediated vasoconstriction; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, producing arterial dilation; and hydrochlorothiazide reduces sodium and water reabsorption in the distal convoluted tubule, decreasing plasma volume. Together they produce additive blood‑pressure‑lowering effects.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Headache: mild to moderate intensity.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness or light‑headedness, especially after the first doses.
• Fatigue: general feeling of tiredness.
• Increased urination: due to the diuretic component.
• Flushing: transient warmth or redness of the skin.

Serious or Rare Side Effects

• Angio‑edema: rapid swelling of the face, lips, tongue or throat.
• Severe hypotension: symptomatic low blood pressure.
• Electrolyte disturbances: notably low potassium or sodium levels.
• Acute kidney injury: sudden decline in renal function.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Blood dyscrasias: rare blood‑cell abnormalities.

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters.

• Renal impairment: adjust dosing and monitor creatinine clearance.
• Hepatic impairment: use with caution; monitor liver function tests.
• Electrolyte imbalance: check potassium and sodium levels regularly.
• Pregnancy: contraindicated in the second and third trimesters; avoid use.
• Concomitant use with other antihypertensives: monitor for additive hypotensive effects.
• Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Olmesartan Medoxil, Amlodipine and Hydrochlorothiazide may interact with several drug classes; careful review of a patient’s medication list is essential.

Major Interactions (Avoid)

• Aliskiren: combined use with ARBs can increase risk of renal impairment and hyperkalaemia.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia.
• Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine plasma levels.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response and affect renal function.
• Lithium: can increase lithium concentrations, risking toxicity.
• ACE inhibitors: additive risk of hypotension and renal dysfunction.
• Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.